Updated time: 2021-03-19 14:48:29
Chronic infection with hepatitis B virus (HBV) can be treated with interferon or nucleos(t)ides analogs (NA). However, while viral replication can be suppressed by current therapy, it remains difficult to completely eradicate the virus from patients. We identified the antiviral activity of miR-130a, miR-204, and miR-1236. Combinations of these microRNAs could be an alternative approach to HBV therapy.
Huang JY, Chen HL, and Shih C. (2016). Scientific Reports 6: 34740.
Huang JY, Chou SF, Lee JW, Chen HL, Chen CM, Tao MH, and Shih C. (2015). RNA 21(3): 385-400.
United States Patent US # 9,771,589 B2. Treating Hepatitis Virus Infection by Modulating MicroRNAs miR-130a, miR-130b, miR-204, and miR-1236. Inventor: Chiaho Shih. 09/2017 – 09/2034.
Treatment for hepatitis B with microRNAs is a new approach. HBV polymerase variants resistant to NA should be sensitive to these antiviral microRNAs.
12A-1020619
US 9,771,589 B2、CN 105899238 B
Chronic infection with hepatitis B
Chiaho Shih、Jyun-Yuan Huang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Cellular microRNAs miR-130a miR-204 and miR-1236 inhibit hepatitis B virus replication